$RCUS
Arcus Biosciences, Inc. Stock $rcus

$rcus Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000172452124000092 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$39.00M	$145.0M	$25.00M
YoY Change	34.48%	480.0%	38.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$30.00M	$32.00M	$30.00M
YoY Change	7.14%	6.67%	25.14%
% of Gross Profit
Research & Development	$115.0M	$109.0M	$81.00M
YoY Change	36.9%	34.57%	32.33%
% of Gross Profit
Depreciation & Amortization	$2.000M	$3.000M	$2.000M
YoY Change	0.0%	50.0%	37.27%
% of Gross Profit
Operating Expenses	$145.0M	$161.0M	$111.0M
YoY Change	29.46%	45.05%	30.3%
Operating Profit	-$106.0M	-$16.00M	-$86.00M
YoY Change	27.71%	-81.4%	28.01%
Interest Expense	$13.00M	$13.00M	$9.000M
YoY Change	44.44%	44.44%	1446.39%
% of Operating Profit
Other Income/Expense, Net	$13.00M	$12.00M	-$1.000M
YoY Change		-1300.0%	-623.56%
Pretax Income	-$93.00M	-$4.000M	-$78.00M
YoY Change	25.68%	-94.87%	16.44%
Income Tax	$0.00	$0.00	$2.000M
% Of Pretax Income
Net Earnings	-$93.00M	-$4.000M	-$80.00M
YoY Change	24.0%	-95.0%	17.66%
Net Earnings / Revenue	-238.46%	-2.76%	-320.0%
Basic Earnings Per Share	-$1.02	-$0.05	-$1.09
Diluted Earnings Per Share	-$1.02	-$0.05	-$1.10
COMMON SHARES
Basic Shares Outstanding	90.95M shares	90.86M shares	73.01M
Diluted Shares Outstanding	91.10M shares	86.20M shares	73.00M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$969.0M	$995.0M	$954.0M
YoY Change	4.19%	4.3%	-21.39%
Cash & Equivalents	$156.0M	$185.0M	$238.0M
Short-Term Investments	$813.0M	$810.0M	$716.0M
Other Short-Term Assets	$20.00M	$29.00M	$25.00M
YoY Change	5.26%	16.0%	34.94%
Inventory
Prepaid Expenses
Receivables	$33.00M	$40.00M	$36.00M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.022B	$1.064B	$1.015B
YoY Change	3.65%	4.83%	-19.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$49.00M	$51.00M	$37.00M
YoY Change	8.89%	37.84%	10.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$40.00M	$100.0M	$90.00M
YoY Change	-50.0%	11.11%	-30.14%
Other Assets	$75.00M	$78.00M	$112.0M
YoY Change	-31.19%	-30.36%	928.75%
Total Long-Term Assets	$164.0M	$229.0M	$239.0M
YoY Change	-29.91%	-4.18%	-14.4%
TOTAL ASSETS
Total Short-Term Assets	$1.022B	$1.064B	$1.015B
Total Long-Term Assets	$164.0M	$229.0M	$239.0M
Total Assets	$1.186B	$1.293B	$1.254B
YoY Change	-2.79%	3.11%	-18.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.00M	$16.00M	$28.00M
YoY Change	25.0%	-42.86%	54.75%
Accrued Expenses	$71.00M	$64.00M	$49.00M
YoY Change	29.09%	30.61%	202.54%
Deferred Revenue	$113.0M	$124.0M
YoY Change	9.71%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$199.0M	$204.0M	$179.0M
YoY Change	10.56%	13.97%	11.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$138.0M	$140.0M	$475.0M
YoY Change	-70.89%	-70.53%	3323.67%
Total Long-Term Liabilities	$138.0M	$140.0M	$475.0M
YoY Change	-70.89%	-70.53%	3323.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$199.0M	$204.0M	$179.0M
Total Long-Term Liabilities	$138.0M	$140.0M	$475.0M
Total Liabilities	$337.0M	$344.0M	$654.0M
YoY Change	-48.47%	-47.4%	-12.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$946.0M	-$853.0M
YoY Change	35.72%
Common Stock	$1.582B	$1.561B
YoY Change	24.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$635.0M	$707.0M	$600.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.186B	$1.293B	$1.254B
YoY Change	-2.79%	3.11%	-18.75%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$93.00M	-$4.000M	-$80.00M
YoY Change	24.0%	-95.0%	17.66%
Depreciation, Depletion And Amortization	$2.000M	$3.000M	$2.000M
YoY Change	0.0%	50.0%	37.27%
Cash From Operating Activities	-$94.00M	-$2.000M	-$98.00M
YoY Change	64.91%	-97.96%	-114.98%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$4.000M	$3.000M
YoY Change	-100.0%	33.33%	7.6%
Acquisitions
YoY Change
Other Investing Activities	$63.00M	-$165.0M	$132.0M
YoY Change	103.23%	-225.0%	-149.76%
Cash From Investing Activities	$63.00M	-$169.0M	$129.0M
YoY Change	142.31%	-231.01%	-148.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.000M	$229.0M	1.000M
YoY Change	-91.3%	22800.0%	-93.3%
NET CHANGE
Cash From Operating Activities	-94.00M	-$2.000M	-98.00M
Cash From Investing Activities	63.00M	-$169.0M	129.0M
Cash From Financing Activities	2.000M	$229.0M	1.000M
Net Change In Cash	-29.00M	$58.00M	32.00M
YoY Change	262.5%	81.25%	-92.02%
FREE CASH FLOW
Cash From Operating Activities	-$94.00M	-$2.000M	-$98.00M
Capital Expenditures	$0.00	$4.000M	$3.000M
Free Cash Flow	-$94.00M	-$6.000M	-$101.0M
YoY Change	51.61%	-94.06%	-115.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2024Q1	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	145000000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25000000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109000000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81000000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32000000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30000000	usd
CY2024Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	20000000	usd
CY2023Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	161000000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	111000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-86000000	usd
CY2024Q1	rcus	Interest And Other Income Expense Nonoperating Net InterestAndOtherIncomeExpenseNonoperatingNet	13000000	usd
CY2023Q1	rcus	Interest And Other Income Expense Nonoperating Net InterestAndOtherIncomeExpenseNonoperatingNet	9000000	usd
CY2024Q1	rcus	Effective Interest On Liability For Sale Of Future Royalties EffectiveInterestOnLiabilityForSaleOfFutureRoyalties	1000000	usd
CY2023Q1	rcus	Effective Interest On Liability For Sale Of Future Royalties EffectiveInterestOnLiabilityForSaleOfFutureRoyalties	1000000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12000000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-78000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-80000000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86200000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	86200000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73000000.0	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73000000.0	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-80000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	185000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	810000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	632000000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	35000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	38000000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34000000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1064000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	831000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	100000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	107000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51000000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	78000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	106000000	usd
CY2024Q1	us-gaap	Assets Assets	1293000000	usd
CY2023Q4	us-gaap	Assets Assets	1095000000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	16000000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	124000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	91000000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	64000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	76000000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	204000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	184000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	242000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	307000000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	140000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	142000000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000.0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000.0	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90900000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90900000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	75500000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75500000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1561000000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1311000000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-853000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-849000000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	707000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	462000000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1293000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1095000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	657000000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-80000000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	600000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	462000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	228000000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	707000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-4000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-80000000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	20000000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	19000000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3000000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2000000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2000000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2000000	usd
CY2024Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	20000000	usd
CY2023Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	6000000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4000000	usd
CY2024Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1000000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-13000000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-6000000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-5000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	8000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10000000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-42000000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-25000000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-12000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-21000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98000000	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	387000000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	154000000	usd
CY2024Q1	rcus	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	222000000	usd
CY2023Q1	rcus	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	284000000	usd
CY2024Q1	rcus	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0	usd
CY2023Q1	rcus	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	2000000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-169000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	129000000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	228000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	229000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	58000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	32000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	130000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	209000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	188000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	241000000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1000000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4000000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	Organization, liquidity and capital resources<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a clinical-stage biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in multiple Phase 3 registrational studies targeting lung and gastrointestinal cancers. Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, we had cash, cash equivalents and marketable securities of $1.1 billion, which we believe will be sufficient to fund our planned operations for a period of at least twelve months following the date of filing of this report.</span></div>
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.</span></div>
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	145000000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25000000	usd
CY2024Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	142000000	usd
CY2023Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	25000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	366000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	398000000	usd
CY2024Q1	rcus	Option Payment For Etrumadenant OptionPaymentForEtrumadenant	100000000	usd
CY2024Q1	rcus	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress And Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice	107000000	usd
CY2024Q1	rcus	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Earnings Per Share Basic ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueEarningsPerShareBasic	1.24
CY2024Q1	rcus	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Earnings Per Share Diluted ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueEarningsPerShareDiluted	1.24
CY2024Q1	rcus	Option Payment For Domvanalimab OptionPaymentForDomvanalimab	87000000	usd
CY2024Q1	rcus	Option Payment For Etrumadenant OptionPaymentForEtrumadenant	100000000	usd
CY2024Q1	rcus	Deferred Revenues At Amendment Closing Date DeferredRevenuesAtAmendmentClosingDate	335000000	usd
CY2024Q1	rcus	Allocation Of Transaction Price AllocationOfTransactionPrice	522000000	usd
CY2024Q1	rcus	Option Payment For Etrumadenant OptionPaymentForEtrumadenant	100000000	usd
CY2024Q1	rcus	Option Payment For Domvanalimab OptionPaymentForDomvanalimab	87000000	usd
CY2024Q1	rcus	Deferred Revenues At Amendment Closing Date DeferredRevenuesAtAmendmentClosingDate	335000000	usd
CY2024Q1	rcus	Allocation Of Transaction Price AllocationOfTransactionPrice	522000000	usd
CY2024Q1	rcus	Etrumadenant License And Research And Development Activities EtrumadenantLicenseAndResearchAndDevelopmentActivities	210000000	usd
CY2024Q1	rcus	Quemliclustat License And Research And Development Activities QuemliclustatLicenseAndResearchAndDevelopmentActivities	168000000	usd
CY2024Q1	rcus	Zimberelimab Research And Development And Commercial Activities ZimberelimabResearchAndDevelopmentAndCommercialActivities	33000000	usd
CY2024Q1	rcus	Access Rights AccessRights	57000000	usd
CY2024Q1	rcus	Option Continuation Periods OptionContinuationPeriods	20000000	usd
CY2024Q1	rcus	Rights To Certain Studies RightsToCertainStudies	34000000	usd
CY2024Q1	rcus	Allocation To Performance Obligations AllocationToPerformanceObligations	522000000	usd
CY2024Q1	rcus	Allocation To Performance Obligations AllocationToPerformanceObligations	35000000	usd
CY2024Q1	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	2000000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	4000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	3000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1095000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	866000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	866000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.023
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18700000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16300000	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20000000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1096000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	185000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	127000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	810000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	632000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	100000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	107000000	usd
CY2024Q1	rcus	Cash Cash Equivalents And Available For Sale Investments CashCashEquivalentsAndAvailableForSaleInvestments	1095000000	usd
CY2023Q4	rcus	Cash Cash Equivalents And Available For Sale Investments CashCashEquivalentsAndAvailableForSaleInvestments	866000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	113	position
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	105	position
CY2023	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
CY2023Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
CY2024Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	185000000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	238000000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3000000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	188000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	241000000	usd
CY2024Q1	rcus	Prepaid Expenses And Other Current Assets PrepaidExpensesAndOtherCurrentAssets	29000000	usd
CY2023Q4	rcus	Prepaid Expenses And Other Current Assets PrepaidExpensesAndOtherCurrentAssets	30000000	usd
CY2024Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	5000000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	4000000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34000000	usd
CY2024Q1	rcus	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	37000000	usd
CY2023Q4	rcus	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	36000000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15000000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	26000000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11000000	usd
CY2024Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1000000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3000000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	64000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	76000000	usd
CY2024Q1	rcus	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	4000000	usd
CY2023Q1	rcus	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	4000000	usd
CY2024Q1	rcus	Recognition Of Tenant Improvement Allowance Receivable RecognitionOfTenantImprovementAllowanceReceivable	0	usd
CY2023Q1	rcus	Recognition Of Tenant Improvement Allowance Receivable RecognitionOfTenantImprovementAllowanceReceivable	4000000	usd
CY2024Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	20000000	usd
CY2024Q1	us-gaap	Security Deposit SecurityDeposit	3000000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	3000000	usd
CY2024Q1	rcus	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress And Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice	107000000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001724521-24-000092-index-headers.html	Edgar Link	pending
0001724521-24-000092-index.html	Edgar Link	pending
0001724521-24-000092.txt	Edgar Link	pending
0001724521-24-000092-xbrl.zip	Edgar Link	pending
a2024q1exhibit311.htm	Edgar Link	pending
a2024q1exhibit312.htm	Edgar Link	pending
a2024q1exhibit321.htm	Edgar Link	pending
a2024q1exhibit322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rcus-20240331.htm	Edgar Link	pending
rcus-20240331.xsd	Edgar Link	pending
rcus-20240331_g1.jpg	Edgar Link	pending
rcus-20240331_g2.jpg	Edgar Link	pending
rcus-20240331_g3.jpg	Edgar Link	pending
rcus-20240331_g4.jpg	Edgar Link	pending
rcus-20240331_g5.jpg	Edgar Link	pending
rcus-20240331_g6.jpg	Edgar Link	pending
rcus-20240331_g7.jpg	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
rcus-20240331_cal.xml	Edgar Link	unprocessable
rcus-20240331_def.xml	Edgar Link	unprocessable
rcus-20240331_lab.xml	Edgar Link	unprocessable
rcus-20240331_pre.xml	Edgar Link	unprocessable
rcus-20240331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RCUS
Arcus Biosciences, Inc. Stock $rcus

2024 Q2 Form 10-Q Financial Statement

#000172452124000092 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RCUS Arcus Biosciences, Inc. Stock $rcus

2024 Q2 Form 10-Q Financial Statement

#000172452124000092 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RCUS
Arcus Biosciences, Inc. Stock $rcus